# Feasibility Assessment: ALS Neuron-Specific Autophagy Hypotheses
---
## Summary Comparison Matrix
| Domain | H1: Axonal Transport (C9orf72/RAB7) | H2: OPTN/TBK1 Mitophagy | H3: TDP-43 SNARE Fusion | H4: VCP Crosstalk |
|--------|-------------------------------------|-------------------------|-------------------------|-------------------|
| **Confidence** | 0.62 | 0.58 | 0.52 | ~0.55 (est.) |
| **Druggability** | Low-Moderate | Moderate-High | Low | High |
| **Biomarker Readiness** | Moderate | Moderate | Low-Moderate | Moderate |
| **Model Systems** | Strong (iPSC MN) | Moderate | Weak | Moderate |
| **Safety Risk** | High | Moderate-High | Moderate | High |
| **Timeline** | Long (>10 yrs) | Medium-Long (7-10 yrs) | Long (>12 yrs) | Medium (5-8 yrs) |
| **Estimated Cost** | Very High | High | Very High | High |
| **Overall Feasibility** | **Moderate-Low** | **Moderate** | **Low** | **Moderate** |
---
## Hypothesis 1: Axonal Transport Defect (C9orf72/RAB7/Dynein)
### Druggability: LOW-MODERATE
- **Primary target (dynein-dynactin)** is a megadalton motor complex with no known small molecule agonists; only inhibitors exist (dynein inhibitors like Ciliobrevin D are research tools, not therapeutics)
- **RAB7A** is more tractable but requires GTPase activation (not just inhibition), an underexplored pharmacology space
- **C9orf72 function restoration** is indirect and mechanistically ambiguous—is mechanism haploinsufficiency or gain-of-toxicity?
- **Delivery challenge**: Motor neuron-targeted delivery across the blood-brain barrier remains unsolved
**Most tractable entry point**: RAB7 nucleotide exchange factors (DENN-domain proteins) as activators—no validated agonists exist but protein-protein interaction modulators are emerging
### Biomarkers/Model Systems: MODERATE
- **Strong model systems**: iPSC-derived motor neurons with live-cell axonal transport assays in microfluidic chambers are well-established and translatable
- **Biomarker candidates**: Axonal degeneration markers (NfL, NfH in CSF/plasma), but none specific to transport defects vs. general neurodegeneration
- **Autophagy flux reporters** (mCherry-eGFP-LC3) work but require invasive sampling
- **Imaging-based biomarkers**: PET tracers for autophagosome accumulation do not exist; super-resolution microscopy needed for mechanistic validation in human tissue
**Validation gap**: No validated blood/CSF biomarker distinguishes transport defects from other ALS autophagy mechanisms
### Clinical Development Constraints
- **Patient stratification**: C9orf72 expansion carriers represent ~40% of familial ALS, but mechanistic heterogeneity within this group is substantial
- **Target engagement assays**: Axonal transport in living patients is not measurable; must rely on surrogate endpoints (NfL trajectory, functional scores)
- **Combination approach likely needed**: Pure transport modulation unlikely to overcome polyglutamine/dipeptide repeat toxicity from the same mutation
- **Regulatory path**: ALS indication with validated enrichment for C9orf72 patients is acceptable; primary endpoint would likely be survival or functional decline (ALSF